Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pumitamig + elfetabart drozuntecan
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pumitamig plus elfetabart drozuntecan is an investigational, "novel-novel" combination of two biologics being developed by BioNTech in collaboration with Bristol Myers Squibb and Duality Biologics. Pumitamig (BNT327/BMS-986545/PM8002) is a bispecific antibody targeting programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A). Elfetabart drozuntecan (BNT324/DB-1311) is an antibody-drug conjugate (ADC) targeting B7-H3 (CD276) conjugated to a topoisomerase I inhibitor payload (drozuntecan) via a cleavable linker. This combination is designed to simultaneously inhibit tumor angiogenesis, block immune checkpoint pathways, and deliver cytotoxic chemotherapy directly to B7-H3-expressing cancer cells. The combination is currently being evaluated in Phase 1b/2 clinical trials for the treatment of advanced or metastatic small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and other advanced solid tumors.
- Other names
- BMS-986545 + BNT324BMS-986545 + DB-1311BNT324 + BNT327BNT327 + BNT324DB-1311 + PM8002PM8002 + DB-1311pumitamig + elfe-Dpumitamig plus elfe-Dpumitamig plus elfetabart drozuntecan
02
Targets
B7-H3PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on pumitamig + elfetabart drozuntecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pumitamig + elfetabart drozuntecan.